Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,515 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,515 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $2.97, for a total value of $16,379.55. Following the transaction, the executive vice president now directly owns 83,814 shares in the company, valued at $248,927.58. This trade represents a 6.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Annexon Trading Down 0.7 %

Shares of NASDAQ:ANNX traded down $0.02 on Thursday, hitting $2.83. The company had a trading volume of 796,392 shares, compared to its average volume of 1,392,680. The stock has a market cap of $301.65 million, a price-to-earnings ratio of -2.70 and a beta of 1.07. The stock has a 50 day moving average price of $4.33 and a 200 day moving average price of $5.59. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ANNX. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon currently has an average rating of “Buy” and an average price target of $15.80.

Institutional Trading of Annexon

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in Annexon during the fourth quarter worth approximately $59,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Annexon during the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. lifted its holdings in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. Forefront Analytics LLC boosted its stake in Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after purchasing an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Annexon in the 4th quarter valued at $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.